2002
DOI: 10.1038/nrc905
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians. What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clinical trials?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

15
893
1
27

Year Published

2004
2004
2010
2010

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 1,396 publications
(936 citation statements)
references
References 130 publications
15
893
1
27
Order By: Relevance
“…Tumor progression may be promoted by both chronic (diffusion-limited) as well as acute (fluctuating) tumor hypoxia (Janssen et al, 2005;Rofstad et al, 2007), and antiangiogenic therapy increases the proportion of cells undergoing both types of hypoxia (Rofstad et al, 2007). Currently, intervention with antiangiogenic agents is performed in relatively late stages of disease, where there are more angiogenic and survival pathways involved and manipulations of any single factor (such as inhibition of vascular endothelial growth factor) likely become less critical for cancer progression Kerbel and Folkman, 2002;Franco et al, 2006). Interestingly, addition of bevacizumab to first-line chemotherapy in patients with metastatic colorectal cancer increased response rates and prolonged overall survival (Hurwitz et al, 2004).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Tumor progression may be promoted by both chronic (diffusion-limited) as well as acute (fluctuating) tumor hypoxia (Janssen et al, 2005;Rofstad et al, 2007), and antiangiogenic therapy increases the proportion of cells undergoing both types of hypoxia (Rofstad et al, 2007). Currently, intervention with antiangiogenic agents is performed in relatively late stages of disease, where there are more angiogenic and survival pathways involved and manipulations of any single factor (such as inhibition of vascular endothelial growth factor) likely become less critical for cancer progression Kerbel and Folkman, 2002;Franco et al, 2006). Interestingly, addition of bevacizumab to first-line chemotherapy in patients with metastatic colorectal cancer increased response rates and prolonged overall survival (Hurwitz et al, 2004).…”
Section: Discussionmentioning
confidence: 99%
“…In spite of the unquestionable successes of some of these antiangiogenic strategies, the responses of individual patients vary markedly (Kerbel and Folkman, 2002;Yang et al, 2003;Miller et al, 2005a, b), in some instances amounting to overt resistance or lack of objective survival benefit (Jubb et al, 2006). While there may be several reasons why a subset of cancer patients exhibit resistance to antiangiogenic agents, it has recently become apparent that this property may reside in the genetic make up of cancer cells (Rak et al, 2006).…”
Section: Introductionmentioning
confidence: 99%
“…On the one hand drug resistance is not likely to appear because the targeted endothelial cell has much greater genetic stability than neoplastic cells (Kerbel and Folkman, 2002). Also drug delivery is likely to be without compromise, as the endothelium of the tumour vasculature is easily accessible.…”
Section: Vdas and Their Targetmentioning
confidence: 99%
“…Tumour angiogenesis (the growth of new blood vessels into tumours) is a key driver of tumour progression and has received considerable attention as a therapeutic target (Hanahan and Folkman, 1996;Kerbel and Folkman, 2002;Ferrara and Kerbel, 2005). One of the most highly studied pro-angiogenic growth factors is vascular endothelial growth factor (VEGF), particularly the VEGF-A isoform, which is highly expressed in a variety of human tumours (Ellis and Hicklin, 2008).…”
Section: Introductionmentioning
confidence: 99%